Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $28 to $36.